In gynecological cancers, the incidence of HER3 overexpression was reported to be 41.3–67.5% for ovarian cancer [5, 27, 28], 30% for endometrial cancer [29], and 31.0–74.7% for cervical cancer [15, 30–32]. This evidence concerns the gene ERBB3 and female reproductive organ cancer.